Search Results

You are looking at 31 - 40 of 110 items for :

  • "aromatase inhibitor" x
  • Refine by Access: All x
Clear All
Full access

Kostandinos Sideras and Charles L. Loprinzi

in women with increased risk by 48%, 8 and raloxifene has shown a similar efficacy with tamoxifen at reducing the risk of invasive breast cancer in the same increased risk population. 9 Given the strong efficacy aromatase inhibitors have shown in

Full access

William J. Gradishar

patients with prior aromatase inhibitor (AI) therapy, “reflecting what we may do in practice when a patient progresses,” he added. The combination doubled the duration of PFS, from 4.6 to 9.6 months. 3 Together, the 3 pivotal trials with palbociclib

Full access

Michelle E. Melisko and Joseph B. Narus

-term use of hormonal agents such as tamoxifen and aromatase inhibitors can cause vasomotor and musculoskeletal symptoms. 3 For both men and women who have had surgery for rectal cancer, sexual problems afterward are “common, multifactorial, inadequately

Full access

Michaela J. Higgins, James M. Rae, David A. Flockhart, Daniel F. Hayes, and Vered Stearns

; 100 : 642 – 648 . 57 Hayes DF Stearns V Rae J . A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst 2008 ; 100 : 610 – 613 . 58 Early Breast Cancer

Full access

Lee S. Schwartzberg and Sarah L. Blair

years. Interestingly, despite a high RS, older patients were far less likely to receive chemotherapy than younger patients. 11 Benefit of Endocrine Therapy The benefit of aromatase inhibitors over tamoxifen extends to both older and younger

Full access

Steven Sorscher

, Phase III, randomized study of dual human epidermal growth factor receptor (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal woman with HER2-positive, hormone receptor-positive metastatic breast

Full access

Michael J. Hassett, Wei Jiang, Melissa E. Hughes, Stephen Edge, Sara H. Javid, Joyce C. Niland, Richard Theriault, Yu-Ning Wong, Deborah Schrag, and Rinaa S. Punglia

diagnosis was defined as documentation of therapy with a selective ER modulator, aromatase inhibitor, or gonadotropin-releasing hormone agonist lasting at least 30 days after diagnosis and starting >30 days before any SBE. Descriptive statistics for the use

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff

in breast cancer (BC) [abstract] . Proc Am Soc Clin Oncol 2002 ; 21 : Abstract 164 . 161 Smith IE Dowsett M Yap YS . Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested

Full access

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

-line versus second- and subsequent-line settings. Preferred First-Line Therapy for HR-Positive, HER2-Negative Breast Cancer Aromatase Inhibitor in Combination With Cyclin-Dependent Kinase 4/6 Inhibitor In postmenopausal women or premenopausal women receiving

Full access

Anthony A. Matthews, Sharon Peacock Hinton, Susannah Stanway, Alexander R. Lyon, Liam Smeeth, Krishnan Bhaskaran, and Jennifer L. Lund

has been suggested that users of the hormone therapy tamoxifen are at an increased risk of venous thromboembolism compared with aromatase inhibitor users, but at a decreased risk of other cardiovascular outcomes, such as coronary heart disease. 36 – 38